Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study

Cancer Prevention Research

Volumn 3, Issue 9, 2010, Pages 1168-1175

  Chow, H H Sherry ^a   Garland, Linda L ^a   Hsu, Chiu Hsieh ^a   Vining, Donna R ^a   Chew, Wade M ^a   Miller, Jessica A ^a   Perloff, Marjorie ^b   Crowell, James A ^b   Alberts, David S ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; BILIRUBIN GLUCURONIDE; BUSPIRONE; CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE; LOSARTAN; RESVERATROL;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DECREASED APPETITE; DIARRHEA; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; FLATULENCE; HEARTBURN; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; INCREASED APPETITE; INSOMNIA; MALE; MENSTRUAL IRREGULARITY; MOOD CHANGE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; SIDE EFFECT; URINE ODOR; VIVID DREAM; VOLUNTEER;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOGENS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME ACTIVATION; FEMALE; HEALTH; HUMAN EXPERIMENTATION; HUMANS; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; STILBENES; YOUNG ADULT;

EID: 77956412951     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0155     Document Type: Article

References (34)

1. Vastano BC, Chen Y, Zhu N, Ho CT, Zhou Z, Rosen RT. Isolation and identification of stilbenes in two varieties of Polygonum cuspidatum. J Agric Food Chem 2000;48:253-6. (Pubitemid 30120350)
2. Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the "French paradox"? Eur J Endocrinol 1998;138:619-20.
3. Delmas D, Lancon A, Colin D, Jannin B, Latruffe N. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets 2006;7:423-42.
4. Signorelli P, Ghidoni R. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J Nutr Biochem 2005;16:449-66.
5. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004;24:2783-840.
6. Athar M, Back JH, Tang X, et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007;224:274-83. (Pubitemid 47575677)
7. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res 2009;2:409-18.
8. Ciolino HP, Daschner PJ, Yeh GC. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res 1998;58:5707-12.
9. Yueh MF, Kawahara M, Raucy J. Cell-based high-throughput bioassays to assess induction and inhibition of CYP1A enzymes. Toxicol In Vitro 2005;19:275-87.
10. Revel A, Raanani H, Younglai E, et al. Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo[a]pyrene. J Appl Toxicol 2003;23:255-61.
11. Mollerup S, Ovrebo S, Haugen A. Lung carcinogenesis: resveratrol modulates the expression of genes involved in the metabolism of PAH in human bronchial epithelial cells. Int J Cancer 2001;92:18-25. (Pubitemid 32187027)
12. Chen ZH, Hurh YJ, Na HK, et al. Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis 2004;25:2005-13.
13. Piver B, Berthou F, Dreano Y, Lucas D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 2001;125:83-91.
14. Chang TK, Yeung RK. Effect of trans-resveratrol on 7-benzyloxy-4- trifluoromethylcoumarin O-dealkylation catalyzed by human recombinant CYP3A4 and CYP3A5. Can J Physiol Pharmacol 2001;79:220-6.
15. Sainz RM, Mayo JC, Tan DX, Lopez-Burillo S, Natarajan M, Reiter RJ. Antioxidant activity of melatonin in Chinese hamster ovarian cells: changes in cellular proliferation and differentiation. Biochem Biophys Res Commun 2003;302:625-34.
16. Szaefer H, Cichocki M, Brauze D, Baer-Dubowska W. Alteration in phase I and II enzyme activities and polycyclic aromatic hydrocarbons-DNA adduct formation by plant phenolics in mouse epidermis. Nutr Cancer 2004;48:70-7.
17. Gerhauser C, Klimo K, Heiss E, et al. Mechanism-based in vitro screening of potential cancer chemopreventive agents. Mutat Res 2003;523-524:163-72.
18. Yen GC, Duh PD, Lin CW. Effects of resveratrol and 4-hexylresorcinol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes. Free Radic Res 2003;37:509-14.
19. Christensen M, Andersson K, Dalen P, et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 2003;73:517-28.
20. Park YH, Kullberg MP, Hinsvark ON. Quantitative determination of dextromethorphan and three metabolites in urine by reverse-phase high-performance liquid chromatography. J Pharm Sci 1984;73:24-9.
21. Lam YWF, Rodriguez SY. High-performance liquid chromatography determination of dextromethorphan and dextrorphan for oxidation phenotyping by fluorescence and ultraviolet detection. Ther Drug Monit 1993;15:300-4.
22. Ritter MA, Furtek CI, Lo MW. An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection. J Pharm Biomed Anal 1997;15:1021-9.
23. Chew W, Xu M-J, Cordova C, Chow H-H. Quantification of a cytochrome P450 3A4 substrate, buspirone, in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2006;844:235-9. (Pubitemid 44792000)
24. Boocock D, Patel KR, Faust GES, et al. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2007;848:182-7.
25. Lilja J, Kivisto K, Backman J, Lamberg T, Neuvonen P. Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 1998;64:655-60.
26. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effect of St. John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001;70:317-26.
27. Boocock DJ, Faust GE, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007;16:1246-52.
28. Uno S, Dalton TP, Shertzer HG, et al. Benzo[a]pyrene-induced toxicity: paradoxical protection in Cyp1a1(-/-) knockout mice having increased hepatic BaP-DNA adduct levels. Biochem Biophys Res Commun 2001;289:1049-56.
29. Uno S, Dalton TP, Derkenne S, et al. Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. Mol Pharmacol 2004;65:1225-37.
30. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-9.
31. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101:113-21.
32. Navarro SL, Peterson S, Chen C, et al. Cruciferous vegetable feeding alters UGT1A1 activity: diet- and genotype-dependent changes in serum bilirubin in a controlled feeding trial. Cancer Prev Res 2009;2:345-52.
33. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995;333:1171-5.
34. Chow HH, Hakim IA, Vining DR, et al. Modulation of human glutathione S-transferases by polyphenon E intervention. Cancer Epidemiol Biomarkers Prev 2007;16:1662-6.